Atyr PHARMA (NASDAQ:ATYR) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note issued to investors on Monday, Marketbeat reports. The firm set an “overweight” rating on the stock.

Other analysts have also recently issued reports about the stock. Wells Fargo & Company began coverage on shares of Atyr PHARMA in a research note on Friday, October 4th. They set an “overweight” rating and a $17.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Atyr PHARMA presently has a consensus rating of “Buy” and a consensus target price of $19.25.

Atyr PHARMA Price Performance

Shares of ATYR opened at $3.89 on Monday. Atyr PHARMA has a 1 year low of $1.39 and a 1 year high of $4.22. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. The company has a fifty day moving average price of $3.31. The company has a market capitalization of $326.53 million, a price-to-earnings ratio of -4.14 and a beta of 1.08.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). Sell-side analysts anticipate that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atyr PHARMA

An institutional investor recently raised its position in Atyr PHARMA stock. JPMorgan Chase & Co. boosted its position in Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,440 shares of the company’s stock after purchasing an additional 10,754 shares during the quarter. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.